# NTLA — slm-full-gpu

## Metadata

ticker: NTLA
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: 79eb3e928a11d45de410521dd8dc7e963e75a207cbe3bc3c7f2718a81f81bb4f
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 653, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 17.013, "latency_s_total": 17.013, "parse_failure": 0, "prompt_tokens": 3136, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 516, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 15.165, "latency_s_total": 15.165, "parse_failure": 0, "prompt_tokens": 3035, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 127, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.993, "latency_s_total": 4.993, "parse_failure": 0, "prompt_tokens": 673, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 146, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 7.12, "latency_s_total": 7.12, "parse_failure": 0, "prompt_tokens": 667, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 184, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.926, "latency_s_total": 5.926, "parse_failure": 0, "prompt_tokens": 591, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 121, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.271, "latency_s_total": 4.271, "parse_failure": 0, "prompt_tokens": 736, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 906, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 10.856, "latency_s_total": 10.856, "parse_failure": 0, "prompt_tokens": 1540, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "NTLA",
  "company_name": "Intellia Therapeutics, Inc.",
  "current_price": 12.75,
  "currency": "USD",
  "market_cap": 1786615296.0,
  "forward_pe": -4.9056764,
  "week_52_high": 28.25,
  "week_52_low": 7.95,
  "financial_currency": "USD",
  "revenue": 59506000.0,
  "net_income": -399975008.0,
  "profit_margin_pct": 0.0,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-26",
    "summary": "Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. In evaluating us and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report on Form 10-K for the year ended December 31, 2025 and in other documents that we file with the Securities and Exchange Commission (\u201cSEC\u201d). If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing us. New risk factors can emerge from time to time, and we cannot predict the impact that any factor or combination of factors may "
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-06",
    "summary": "Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. In evaluating us and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2025, and in other documents that we file with the Securities and Exchange Commission (\u201cSEC\u201d). If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing us. New risk factors can emerge from time to time, and we cannot predict the impact that any f"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the Annual Report on Form 10-K for the year ended December 31, 2025, the key takeaways regarding risk factors for NTLA (NTLA) include:

**1. Unproven Technology and Development Risks**
*   CRISPR genome editing technology is relatively new, and its therapeutic utility, particularly for *in vivo* therapies, is largely unproven.
*   The company’s approaches to discovering and developing novel therapeutics are unproven and may never result in marketable products.
*   Success requires solving complex issues, such as safely delivering therapeutic agents into target cells, optimizing efficacy and specificity, and demonstrating safety, potency, and purity. There is no assurance these issues will be resolved.
*   Progress in developing one CRISPR-based product does not guarantee success in others.

**2. Regulatory and Approval Uncertainties**
*   While one CRISPR-edited *ex vivo* therapy has been approved in the U.S. and EU, no genome editing *in vivo* therapy has been approved in these or other key jurisdictions.
*   Regulatory agencies (such as the FDA, MHRA, and EMA) have limited or no experience with the clinical development of CRISPR-based therapeutics, particularly *in vivo* ones, which may lead to additional testing requirements or delays.
*   The company is in clinical-stage development for nexiguran ziclumeran (NTLA-2001, pending resolution of a clinical hold on the MAGNITUDE trial) and lonvoguran ziclumeran (NTLA-2002), but approval remains uncertain.

**3. Clinical Trial Challenges**
*   The company faces numerous potential delays and unforeseen events during clinical trials, including:
    *   Difficulty obtaining regulatory authorization (IND applications).
    *   Inability to enroll sufficient subjects or slower-than-anticipated enrollment rates.
    *   Trials failing to show safety or efficacy, or producing negative/inconclusive results.
    *   Issues with third-party contractors, clinical trial sites, or investigators failing to comply with protocols.
    *   Insufficient or inadequate supply of product candidates or materials.
    *   Inadequate or non-existent animal models for certain human diseases.

**4. Commercialization and Adoption Risks**
*   Public perception, media coverage, and ethical concerns regarding genome editing may negatively impact subject participation in trials and physician/patient acceptance of treatments.
*   Physicians, healthcare providers, and payors are often slow to adopt new, complex, or costly technologies. Physicians may be unwilling to undergo necessary training or may deem the therapies too risky.
*   Certain patients may not be candidates for therapies due to health conditions or genetic profiles.
*   The company may need to establish sales and marketing capabilities, which presents additional challenges.

**5. Financial Implications**
*   If the company fails to develop viable product candidates, achieve regulatory approval, or successfully market and sell products, it may never achieve profitability.
*   Costs for preclinical studies and clinical trials may exceed expectations.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Unproven Technology and Development Risks:** CRISPR genome editing technology, particularly in vivo applications, is relatively new and its therapeutic utility is largely unproven. The approaches to discover and develop novel therapeutics using CRISPR systems are unproven and may never lead to marketable products. There is no assurance that the company will successfully solve issues related to safe delivery, efficacy, specificity, potency, purity, and safety.
*   **Regulatory Approval Uncertainty:** While one CRISPR-edited ex vivo therapy has been approved in the U.S. and EU, no genome editing in vivo therapy has been approved in these or other key jurisdictions. The potential to obtain approval for any CRISPR product candidates remains uncertain.
*   **Profitability and Commercialization Risks:** If the company fails to develop viable product candidates, achieve regulatory approval, or successfully market and sell products, it may never achieve profitability. Success is highly dependent on the development of CRISPR-based technologies, delivery methods, and therapeutic applications.
*   **Public Perception and Adoption Barriers:** Public perception, media coverage of safety or efficacy issues, and ethical concerns regarding genome editing may negatively impact clinical trial participation and the acceptance of treatments by physicians and patients. Healthcare providers and payors may be slow to adopt new technologies due to upfront costs, training requirements, and complexity.
*   **Legislative and Regulatory Changes:** Responses by government agencies to negative public perception or ethical concerns may result in new legislation, regulations, or medical standards that could limit the ability to develop, commercialize, or obtain regulatory approval for product candidates.
*   **Clinical Development Challenges:** Clinical development is lengthy, expensive, and uncertain. All programs are in early stages (discovery, preclinical, or clinical). There is no guarantee that clinical trials will begin or complete on schedule, that endpoints will be met, or that preclinical and clinical data will predict future success. Interim results do not necessarily predict final results, and trials can fail at any stage.
*   **Manufacturing and Operational Risks:** Generating revenue requires substantial investment, establishing manufacturing capabilities, securing commercial manufacturing capacity, and significant marketing efforts. The company may incur additional costs, experience delays, or be unable to complete development and commercialization.
*   **Unforeseen Events:** The company may experience unforeseen events during clinical trials that could delay or prevent marketing approval or commercialization, including challenges in obtaining regulatory authorization to conduct trials.

## Pre-written sections (judge input)

### Financial Health

Intellia Therapeutics, Inc. (NTLA) currently trades at $12.75 with a market capitalization of approximately $1.79 billion. The company reported revenue of $59.5 million but incurred a net loss of nearly $400 million, resulting in a negative profit margin and a forward P/E ratio of -4.91. This significant net loss highlights the substantial cash burn typical of early-stage biotechnology firms focused on R&D. Consequently, the stock remains highly speculative, with financial performance heavily dependent on future commercialization milestones rather than current profitability.

### Recent Developments

Intellia Therapeutics recently filed its Annual Report on Form 10-K for the year ended December 31, 2025, highlighting significant risk factors that could materially adversely affect the company's business and financial condition. The filing underscores the high degree of risk inherent in investing in the company's common stock, urging careful consideration of these uncertainties. With a current stock price of $12.75 and a negative forward P/E ratio, investors should remain cautious as the company navigates these potential challenges. The upcoming Quarterly Report on Form 10-Q, due in August 2026, will provide further insight into the company's ongoing operational and financial health.

### SEC Filing Highlights
Intellia Therapeutics highlights significant risks associated with its unproven *in vivo* CRISPR technology, noting that no genome editing therapies of this type have yet received regulatory approval in key jurisdictions. The company faces substantial clinical and regulatory hurdles, including a pending resolution to the clinical hold on the MAGNITUDE trial for nexiguran ziclumeran and potential delays due to limited agency experience with *in vivo* development. Additionally, commercialization challenges such as slow adoption by healthcare providers, ethical concerns, and high development costs pose ongoing threats to achieving profitability.

### Risk Factors

*   **Unproven Technology and Clinical Uncertainty:** In vivo CRISPR genome editing is a nascent field with no approved therapies in key jurisdictions; the company faces significant risks regarding safe delivery, efficacy, and specificity, with no guarantee that early-stage programs will meet clinical endpoints or achieve regulatory approval.
*   **Regulatory, Legislative, and Public Perception Barriers:** The company is vulnerable to evolving government regulations, ethical concerns, and negative public perception regarding genome editing, which could restrict clinical trial participation, delay approvals, or limit commercial adoption by physicians and payors.
*   **Profitability and Commercialization Challenges:** As a pre-revenue company, Intellia faces substantial risks in achieving profitability due to the high costs of clinical development, manufacturing scale-up, and marketing, with success heavily dependent on the eventual viability and market acceptance of its CRISPR-based technologies.

## Audited (Exec Summary + Outlook)

### Executive Summary
Intellia Therapeutics is a pioneering biotechnology firm focused on developing *in vivo* CRISPR genome editing therapies, currently trading at $12.75 with a market capitalization of approximately $1.79 billion. The stock is notable for its high-risk profile, characterized by a net loss of nearly $400 million against $59.5 million in revenue, reflecting the substantial cash burn inherent in its early-stage R&D phase. The single most important near-term variable shaping the investment outcome is the resolution of the clinical hold on the MAGNITUDE trial for nexiguran ziclumeran and the subsequent regulatory path for its unproven *in vivo* technology.

### Outlook
The directional outlook for Intellia is cautiously constructive but heavily weighted toward binary clinical and regulatory events. Tailwinds include the potential first-mover advantage in *in vivo* CRISPR editing if safety and efficacy profiles are validated, while headwinds consist of persistent ethical concerns, limited agency experience with this technology, and the high cash burn rate evident in the recent financials. Investors should closely monitor the resolution of the clinical hold on the MAGNITUDE trial and the company’s ability to manage development costs without excessive dilution. A positive resolution to the clinical hold and clear regulatory pathways would significantly strengthen the thesis, whereas further delays or negative safety signals would likely weaken investor confidence and exacerbate liquidity concerns.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "currently trading at $12.75"
LABEL: SUPPORTED
REASON: The source data explicitly lists `"current_price": 12.75`.

---

CLAIM: "market capitalization of approximately $1.79 billion"
LABEL: SUPPORTED
REASON: Source data shows `"market_cap": 1786615296.0`; $1,786,615,296 rounds to approximately $1.79 billion, confirmed by the pre-written Financial Health section.

---

CLAIM: "net loss of nearly $400 million"
LABEL: SUPPORTED
REASON: Source data shows `"net_income": -399975008.0`, which is approximately $400 million, consistent with "nearly $400 million."

---

CLAIM: "$59.5 million in revenue"
LABEL: SUPPORTED
REASON: Source data shows `"revenue": 59506000.0`, which rounds to $59.5 million.

---

CLAIM: "resolution of the clinical hold on the MAGNITUDE trial for nexiguran ziclumeran"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights section explicitly states "nexiguran ziclumeran (NTLA-2001, pending resolution of a clinical hold on the MAGNITUDE trial)," and this is echoed in the SEC Filing Highlights pre-written section.

---

**OUTLOOK**

---

CLAIM: "potential first-mover advantage in *in vivo* CRISPR editing if safety and efficacy profiles are validated"
LABEL: INFERENCE
REASON: The source data confirms no *in vivo* CRISPR therapy has been approved in key jurisdictions, making a first-mover advantage a direct logical inference from that stated fact, though the specific phrase "first-mover advantage" does not appear in the source.

---

CLAIM: "limited agency experience with this technology"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states "Regulatory agencies (such as the FDA, MHRA, and EMA) have limited or no experience with the clinical development of CRISPR-based therapeutics, particularly *in vivo* ones."

---

CLAIM: "high cash burn rate evident in the recent financials"
LABEL: SUPPORTED
REASON: The net loss of ~$400 million against $59.5 million in revenue is explicitly present in the source data and directly supports characterizing the cash burn rate as high; the pre-written Financial Health section also uses the phrase "substantial cash burn."

---

CLAIM: "resolution of the clinical hold on the MAGNITUDE trial" (Outlook, second mention)
LABEL: SUPPORTED
REASON: Same basis as above — explicitly stated in the RAG — SEC Highlights and SEC Filing Highlights sections.

---

**Summary of findings:** All quantitative figures ($12.75 price, ~$1.79B market cap, ~$400M net loss, $59.5M revenue) are directly supported by the source data. The named product milestone (MAGNITUDE trial clinical hold for nexiguran ziclumeran) is explicitly present in the SEC filing summaries and RAG highlights. The "first-mover advantage" claim is labeled INFERENCE as it is a logical derivation from the confirmed absence of any approved *in vivo* CRISPR therapy. No claims were found to be UNSUPPORTED.
